The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival

American Journal of Transplantation

Volumn 15, Issue 8, 2015, Pages 2197-2202

  Wiebe, C ^a   Nevins, T E ^b   Robiner, W N ^b   Thomas, W ^c   Matas, A J ^d   Nickerson, P W ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

graft survival; immunogenetics; kidney transplantation: living donor; rejection: acute; risk assessment risk stratification

Indexed keywords

AZATHIOPRINE; EPITOPE; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; MYCOPHENOLATE MOFETIL; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; EPITOPE MISMATCH; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HLA TYPING; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT REFUSAL; GRAFT REJECTION; IMMUNOLOGY;

ADULT; EPITOPES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 84937520081     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13341     Document Type: Article

References (18)

1. Duquesnoy RJ,. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67: 847-862.
2. El-Awar N, Terasaki PI, Cai J, Deng CT, Ozawa M, Nguyen A,. Epitopes of the HLA-A, B, C, DR, DQ and MICA antigens. Clin Transpl 2007; 175-194.
3. Wiebe C, Pochinco D, Blydt-Hansen TD, et al., Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013; 13: 3114-3122.
4. Wiebe C, Nickerson P,. Acceptable mismatching at the class II epitope level: The Canadian experience. Curr Opin Organ Transplant 2014; 19: 442-446.
5. Wiebe C, Gibson IW, Blydt-Hansen TD, et al., Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
6. Nevins TE, Kruse L, Skeans MA, Thomas W,. The natural history of azathioprine compliance after renal transplantation. Kidney Int 2001; 60: 1565-1570.
7. Nevins TE, Thomas W,. Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation 2009; 87: 711-718.
8. Nevins TE, Robiner WN, Thomas W,. Predictive patterns of early medication adherence in renal transplantation. Transplantation 2014; 98: 878-884.
9. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC,. Frequency and impact of non-adherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004; 77: 769-776.
10. Kiberd JA, Acott P, Kiberd BA,. Kidney transplant survival in pediatric and young adults. BMC Nephrol 2011; 12: 54.
11. Maiers M, Gragert L, Klitz W,. High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 2007; 68: 779-788.
12. Laux G, Mansmann U, Deufel A, Opelz G, Mytilineos J,. A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation 2003; 75: 1527-1532.
13. Haririan A, Fagoaga O, Daneshvar H, et al., Predictive value of human leucocyte antigen epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. Clin Transplant 2006; 20: 226-233.
14. Dew MA, DiMartini AF, De Vito Dabbs A, et al., Rates and risk factors for non-adherence to the medical regimen after adult solid organ transplantation. Transplantation 2007; 83: 858-873.
15. Sellarés J, de Freitas DG, Mengel M, et al., Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and non-adherence. Am J Transplant 2011; 12: 388-399.
16. Budde K, Becker T, Arns W, et al., Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. The Lancet 2011; 377: 837-847.
17. Liefeldt L, Brakemeier S, Glander P, et al., Donor-Specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192-1198.
18. Sapir-Pichhadze R, Tinckam K, Quach K, et al., HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: A nested case-control study. Am J Transplant 2014; 15: 137-148.